NCT00947895终止2 期
Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study
Neurologique Foundation, Inc.1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2009年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Improvement in EDSS (Expanded Disability Status Scale) and Kurtzke Functional Scale (to assess individual disabilities).
研究概览
简要总结
The purpose of this study is to compare intramuscular (IM) ACTH (adrenocorticotropin hormone) and intravenous (IV) methylprednisolone (Solumedrol) for the treatment of an MS (Multiple Sclerosis) relapse (exacerbation) after sub-response to an initial 3 day course of IV methylprednisolone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •male or female
- •females of childbearing potential must:
- •have negative pregnancy tests prior to entry into the Double-blind Treatment Phase
- •agree to use adequate contraception during the treatment.
- •females who are either post-menopausal for 12 months prior to randomization or surgically sterile (if documented), may be included without above requirements
- •≥ 18 years of age
- •sign written informed consent prior to participating in the study (Appendix 1)
- •willing and able to comply with trial requirements, including visit schedule and completion of scales
- •diagnosis of multiple sclerosis by 2005 revised McDonald criteria (Appendix 3)
- •an Expanded Disability Status Scale (EDSS) score of 0-6.0 inclusive
- •currently taking a stable dose of an injectable MS disease modifying agent for the preceding 6 months or greater prior to the study-entry relapse
- •in the opinion of their treating physician should undergo a 3 - 5 day course of IV methylprednisolone
排除标准
- •a manifestation of MS other than relapsing
- •initial IV MP greater than 14 days after from start of presenting relapse
- •a history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome
- •a known or 'new' diagnosis of diabetes mellitus (if screening blood glucose is suspicious for diabetes [≥126 mg/dL or ≥7 mmol/L if fasting; ≥200 mg/dL or 11.1 mmol/L if random testing] a patient should be further evaluated for diabetes mellitus)
- •a contraindication to steroid therapy, e.g., peptic ulcer, psychotic states or severe hypertension
- •sensitivity to proteins of porcine origin
- •a known or 'new' diagnosis of severe depression as defined by a score greater than 30 on the Beck Depression Inventory (BDI)
- •a known or 'new' diagnosis of hypothyroidism not adequately controlled with medication
- •treatment with Natalizumab in the past 6 months
- •active systemic bacterial, viral or fungal infections, or diagnosis of AIDS, Hepatitis B, Hepatitis C infection defined as a positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests, respectively
- •have received total lymphoid irradiation or bone marrow transplantation
- •have been treated with corticosteroids or adrenocorticotropic hormones (ACTH) within 1 month prior to Pre-Randomization Phase
- •any medically unstable condition, as assessed by the primary treating physician
- •any of the following neurologic/psychiatric disorders:
- •history of substance abuse (drug or alcohol) or any other factor (i.e., serious psychiatric condition) that may interfere with the subject's ability to cooperate and comply with the study procedures;
- •progressive neurological disorder, other than MS, which may affect participation in the study or require the use of medications not allowed by the protocol
- •any of the following abnormal laboratory values:
- •serum creatinine greater than 1.7 mg/dL (150 μmol/L)
- •white blood cell (WBC) count <3,500/mm3 (<3.5 X 109 / L)
- •lymphocyte count <800/mm3 (<0.8 X 109 / L)
研究组 & 干预措施
Methylprednisolone
Active Comparator
Intravenous (IV) methylprednisolone (Solumedrol) 1000 mg daily for 3 days.
干预措施: Methylprednisolone (Drug)
Methylprednisolone
Active Comparator
Intravenous (IV) methylprednisolone (Solumedrol) 1000 mg daily for 3 days.
干预措施: IM placebo (Other)
ACTH
Active Comparator
Intramuscular (IM) ACTH 80 mg/day for 5 days.
干预措施: ACTH (Drug)
ACTH
Active Comparator
Intramuscular (IM) ACTH 80 mg/day for 5 days.
干预措施: IV placebo (Other)
结局指标
主要结局
Improvement in EDSS (Expanded Disability Status Scale) and Kurtzke Functional Scale (to assess individual disabilities).
时间窗: 12 weeks
次要结局
- Improvement in MSFC (Multiple Sclerosis Functional Composite)18 and its three individual components.(12 weeks)
- Safety and tolerability of ACTH and MP in patients with an acute relapse of multiple sclerosis after sub-response to an initial course of intravenous methylprednisolone.(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pulse ACTH vs. MP for MSMultiple SclerosisNCT01049451University of Southern California23
撤回
4 期
Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal VolunteersAdrenal InsufficiencyNCT03752190Johns Hopkins University
已完成
不适用
Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism(ADOPA)Primary AldosteronismNCT04461535Chongqing Medical University228
撤回
2 期
Repeated High-dose Inhaled Corticosteroids for AsthmaAsthmaNCT00695604University of Chicago
招募中
不适用
Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis(GHOA)Arthritis ShoulderNCT04949087Rush University Medical Center200